Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 131

1.

Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients.

Zangari M, Esseltine D, Cavallo F, Neuwirth R, Elice F, Burns MJ, Yaccoby S, Richardson P, Sonneveld P, Tricot G.

Am J Hematol. 2007 Sep;82(9):831-3.

PMID:
17546639
[PubMed - indexed for MEDLINE]
2.

Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma.

Zangari M, Esseltine D, Lee CK, Barlogie B, Elice F, Burns MJ, Kang SH, Yaccoby S, Najarian K, Richardson P, Sonneveld P, Tricot G.

Br J Haematol. 2005 Oct;131(1):71-3.

PMID:
16173965
[PubMed - indexed for MEDLINE]
3.

Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors.

Dimopoulos MA, Roussou M, Gavriatopoulou M, Zagouri F, Migkou M, Matsouka C, Barbarousi D, Christoulas D, Primenou E, Grapsa I, Terpos E, Kastritis E.

Clin Lymphoma Myeloma. 2009 Aug;9(4):302-6. doi: 10.3816/CLM.2009.n.059.

PMID:
19717380
[PubMed - indexed for MEDLINE]
4.

Bortezomib in combination with conventional chemotherapeutic agents for multiple myeloma compared with bortezomib alone.

Min CK, Lee MJ, Eom KS, Lee S, Lee JW, Min WS, Kim CC, Kim M, Lim J, Kim Y, Han K.

Jpn J Clin Oncol. 2007 Dec;37(12):961-8. Epub 2007 Dec 21.

PMID:
18156171
[PubMed - indexed for MEDLINE]
Free Article
5.

Response to bortezomib and activation of osteoblasts in multiple myeloma.

Zangari M, Yaccoby S, Cavallo F, Esseltine D, Tricot G.

Clin Lymphoma Myeloma. 2006 Sep;7(2):109-14. Review.

PMID:
17026821
[PubMed - indexed for MEDLINE]
6.

High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program.

Mikhael JR, Belch AR, Prince HM, Lucio MN, Maiolino A, Corso A, Petrucci MT, Musto P, Komarnicki M, Stewart AK.

Br J Haematol. 2009 Jan;144(2):169-75. doi: 10.1111/j.1365-2141.2008.07409.x. Epub 2008 Nov 19.

PMID:
19036114
[PubMed - indexed for MEDLINE]
7.

Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib.

Sood R, Carloss H, Kerr R, Lopez J, Lee M, Druck M, Walters IB, Noga SJ.

Am J Hematol. 2009 Oct;84(10):657-60. doi: 10.1002/ajh.21517.

PMID:
19731393
[PubMed - indexed for MEDLINE]
8.

Therapy with bortezomib plus dexamethasone induces osteoblast activation in responsive patients with multiple myeloma.

Ozaki S, Tanaka O, Fujii S, Shigekiyo Y, Miki H, Choraku M, Kagawa K, Asano J, Takeuchi K, Kitazoe K, Hashimoto T, Abe M, Matsumoto T.

Int J Hematol. 2007 Aug;86(2):180-5.

PMID:
17875535
[PubMed - indexed for MEDLINE]
9.

Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment.

Heider U, Kaiser M, Müller C, Jakob C, Zavrski I, Schulz CO, Fleissner C, Hecht M, Sezer O.

Eur J Haematol. 2006 Sep;77(3):233-8.

PMID:
16923110
[PubMed - indexed for MEDLINE]
10.

[Very good partial response and long time to progression by short-term bortezomib plus dexamethasone therapy for a patient with relapsed and refractory multiple myeloma-a case report].

Fukushima T, Iwao H, Nakajima A, Miki M, Sakai T, Sawaki T, Tanaka M, Masaki Y, Hirose Y, Umehara H.

Gan To Kagaku Ryoho. 2009 Aug;36(8):1387-9. Japanese.

PMID:
19692786
[PubMed - indexed for MEDLINE]
11.

The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma.

Niesvizky R, Richardson PG, Rajkumar SV, Coleman M, Rosiñol L, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Boral AL, Esseltine DL, Anderson KC, Bladé J.

Br J Haematol. 2008 Oct;143(1):46-53. doi: 10.1111/j.1365-2141.2008.07303.x. Epub 2008 Jul 31.

PMID:
18673366
[PubMed - indexed for MEDLINE]
12.

A retrospective analysis of bortezomib therapy for Japanese patients with relapsed or refractory multiple myeloma: beta2-microglobulin associated with time to progression.

Ohguchi H, Sugawara T, Ishikawa I, Okuda M, Tomiya Y, Yamamoto J, Onishi Y, Fujiwara Yamada M, Ishizawa K, Kameoka J, Harigae H.

Int J Hematol. 2009 Apr;89(3):342-7. doi: 10.1007/s12185-009-0279-4. Epub 2009 Mar 19.

PMID:
19296199
[PubMed - indexed for MEDLINE]
13.

Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma.

Jagannath S, Barlogie B, Berenson JR, Siegel DS, Irwin D, Richardson PG, Niesvizky R, Alexanian R, Limentani SA, Alsina M, Esseltine DL, Anderson KC.

Br J Haematol. 2008 Nov;143(4):537-40. doi: 10.1111/j.1365-2141.2008.07359.x. Epub 2008 Sep 6.

PMID:
18783399
[PubMed - indexed for MEDLINE]
14.

Hematology: Bortezomib in newly diagnosed multiple myeloma.

Berenson JR.

Nat Rev Clin Oncol. 2009 May;6(5):255-6. doi: 10.1038/nrclinonc.2009.47.

PMID:
19390550
[PubMed - indexed for MEDLINE]
15.

Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma.

Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, San Miguel JF, Cavenagh JD, Anderson KC.

Br J Haematol. 2007 Jun;137(5):429-35. Epub 2007 Apr 19.

PMID:
17451408
[PubMed - indexed for MEDLINE]
16.

Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.

Badros A, Goloubeva O, Dalal JS, Can I, Thompson J, Rapoport AP, Heyman M, Akpek G, Fenton RG.

Cancer. 2007 Sep 1;110(5):1042-9. Review.

PMID:
17654660
[PubMed - indexed for MEDLINE]
Free Article
17.

Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.

Richardson PG, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, Miguel JS, Bladé J, Boccadoro M, Cavenagh J, Alsina M, Rajkumar SV, Lacy M, Jakubowiak A, Dalton W, Boral A, Esseltine DL, Schenkein D, Anderson KC.

Blood. 2007 Nov 15;110(10):3557-60. Epub 2007 Aug 9.

PMID:
17690257
[PubMed - indexed for MEDLINE]
Free Article
18.

Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.

Eom HS, Min CK, Cho BS, Lee S, Lee JW, Min WS, Kim CC, Kim M, Kim Y.

Jpn J Clin Oncol. 2009 Jul;39(7):449-55. doi: 10.1093/jjco/hyp046. Epub 2009 Jun 1.

PMID:
19487425
[PubMed - indexed for MEDLINE]
Free Article
19.

Clinical value of absolute lymphocyte counts before bortezomib-dexamethasone therapy in relapsed multiple myeloma patients.

Song MK, Chung JS, Joo YD, Lee SM, Lee GW, Lee HS, Kim SH, Yun EY, Seol YM, Kim SG, Shin HJ, Choi YJ, Cho GJ.

Acta Haematol. 2010;124(1):34-9. doi: 10.1159/000313654. Epub 2010 Jul 3.

PMID:
20606414
[PubMed - indexed for MEDLINE]
20.

Low dose Velcade, thalidomide and dexamethasone (LD-VTD): an effective regimen for relapsed and refractory multiple myeloma patients.

Ciolli S, Leoni F, Gigli F, Rigacci L, Bosi A.

Leuk Lymphoma. 2006 Jan;47(1):171-3.

PMID:
16321846
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk